U.S. markets close in 46 minutes

Acacia Pharma Group plc (ACPGF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
2.72000.0000 (0.00%)
As of 3:27PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.7200
Open2.7200
BidN/A x N/A
AskN/A x N/A
Day's Range2.7200 - 2.7200
52 Week Range2.7200 - 3.4600
Volume2,500
Avg. Volume0
Market Cap231.127M
Beta (5Y Monthly)2.00
PE Ratio (TTM)N/A
EPS (TTM)-0.4550
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Correction: Transparency Notification - PDF of Notification attached
    GlobeNewswire

    Correction: Transparency Notification - PDF of Notification attached

    THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION. PUBLICATION RELATING TO A TRANSPARENCY NOTIFICATION(ARTICLE 14, 1ST PARAGRAPH, OF THE LAW OF 2 MAY 2007 ON THE DISCLOSURE OF MAJOR HOLDINGS) Acacia Pharma Group plc 1. Summary of the notification Cambridge, UK and Indianapolis, US – 01 July 2021, 08:00 CEST: Acacia Pharma Group plc has received a transparency notification dated 30 June 2021 indicating that Coltrane Asset Management L.P. now holds, by virtue of the sale of shares on 25 June 2021,

  • Transparency Notification
    GlobeNewswire

    Transparency Notification

    THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION. PUBLICATION RELATING TO A TRANSPARENCY NOTIFICATION(ARTICLE 14, 1ST PARAGRAPH, OF THE LAW OF 2 MAY 2007 ON THE DISCLOSURE OF MAJOR HOLDINGS) Acacia Pharma Group plc 1. Summary of the notification Cambridge, UK and Indianapolis, US – 01 July 2021, 08:00 CEST: Acacia Pharma Group plc has received a transparency notification dated 30 June 2021 indicating that Coltrane Asset Management L.P. now holds, by virtue of the sale of shares on 25 June 2021,

  • Significant Continued Progress with Formulary Uptake of BARHEMSYS® and BYFAVO™ in the US
    GlobeNewswire

    Significant Continued Progress with Formulary Uptake of BARHEMSYS® and BYFAVO™ in the US

    This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Acacia Pharma Announces Significant Continued Progress with Formulary Uptake of BARHEMSYS® and BYFAVO™ in the US Cambridge, UK and Indianapolis, US – 1 July 2021: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the